The 9 most recent market catalysts affecting $BHVN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Bearish
Impact 85
Biohaven shares are trading lower after the company announced the FDA ordered a pause on new enrollment in BHV-7000 program and issued a partial clinical hold on September 4, pending additional nonclinical metabolite data.
This FDA clinical hold is a major negative catalyst for Biohaven, directly impacting its lead pipeline candidate, BHV-7000. The pause in new enrollment and partial hold signal regu…
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 75
Biohaven Discloses That FDA Demanded Pause In BHV7000-303 Enrolment; Dosing Continues And Topline Data Readout Remains On Timeline For H2 2026
Biohaven received a partial clinical hold from the FDA, pausing new patient enrollment for its Kv7 ion channel program (BHV-7000) due to insufficient information regarding a specif…
Sep 8, 2026
Corporate Catalyst
Bearish
Impact 65
RBC Capital Downgrades Biohaven to Sector Perform, Lowers Price Target to $19
RBC Capital's downgrade of Biohaven (BHVN) from Outperform to Sector Perform, coupled with a price target reduction from $23 to $19, indicates a less optimistic view from the analy…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 95
Why Is Biohaven Stock Soaring Wednesday?
Biohaven (BHVN) experienced a significant positive catalyst due to two major announcements. First, a global licensing agreement with SK Biopharmaceuticals for its Kv7 platform, inc…
Aug 26, 2026
Corporate Catalyst
Neutral
Impact 92
Biohaven Licenses Kv7 Platform And Epilepsy Candidate Opakalim To SK Biopharmaceuticals In Deal Worth Up To $795M, Biohaven To Receive $400M Upfront
Biohaven has entered into a licensing agreement with SK Biopharmaceuticals for its Kv7 platform and the epilepsy candidate opakalim. This is a major positive catalyst for Biohaven …
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Biohaven, Raises Price Target to $23
RBC Capital analyst Leonid Timashev maintained an 'Outperform' rating on Biohaven (BHVN) and raised the price target from $22 to $23. This action signals continued confidence from …
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 92
Biohaven Q2 Adj. EPS $(0.78) Misses $(0.73) Estimate
Biohaven announced its Q2 adjusted EPS of $(0.78), which fell short of the analyst consensus estimate of $(0.73). This 6.85% miss indicates that the company's financial performance…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 55
Biohaven And Yale University Announce Federal Jury Verdict In Their Favor In Trade Secret Misappropriation And Breach Of Contract Litigation Against Avilar Therapeutics And RA Capital
A federal jury found Avilar Therapeutics and RA Capital liable for willfully and maliciously misappropriating a Yale trade secret (the MODA platform) and for RA Capital breaching a…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.